You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFosinopril
Accession NumberDB00492  (APRD00526)
TypeSmall Molecule
GroupsApproved
DescriptionFosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Structure
Thumb
Synonyms
(2S,4S)-4-Cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
(2S,4S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
(S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
Fosinopril
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-fosinopriltablet20 mgoralAvanstra Inc2011-11-282014-08-21Canada
Ava-fosinopriltablet10 mgoralAvanstra Inc2011-11-282014-08-21Canada
Fosinopril Tabletstablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Fosinopril Tabletstablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Fosinopril-10tablet10 mgoralPro Doc Limitee2008-10-23Not applicableCanada
Fosinopril-20tablet20 mgoralPro Doc Limitee2008-10-23Not applicableCanada
Jamp-fosinopriltablet20 mgoralJamp Pharma Corporation2010-05-17Not applicableCanada
Jamp-fosinopriltablet10 mgoralJamp Pharma Corporation2010-05-17Not applicableCanada
Lin-fosinopriltablet20 mgoralLinson Pharma Co.2004-03-302008-07-16Canada
Lin-fosinopriltablet10 mgoralLinson Pharma Co.2004-03-302008-07-16Canada
Monopril Tab 10mgtablet10 mgoralBristol Myers Squibb Canada1992-12-312013-06-17Canada
Monopril Tab 20mgtablet20 mgoralBristol Myers Squibb Canada1992-12-312013-06-17Canada
Mylan-fosinopriltablet10 mgoralMylan Pharmaceuticals Ulc2004-12-21Not applicableCanada
Mylan-fosinopriltablet20 mgoralMylan Pharmaceuticals Ulc2004-12-21Not applicableCanada
Nu-fosinopriltablet10 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-fosinopriltablet20 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-fosinopriltablet10 mgoralPharmel IncNot applicableNot applicableCanada
PHL-fosinopriltablet20 mgoralPharmel IncNot applicableNot applicableCanada
PMS-fosinopriltablet10 mgoralPharmascience Inc2005-02-08Not applicableCanada
PMS-fosinopriltablet20 mgoralPharmascience Inc2005-02-08Not applicableCanada
Ran-fosinopriltablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-08-15Not applicableCanada
Ran-fosinopriltablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-08-15Not applicableCanada
Ratio Fosinopriltablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-02-082008-08-01Canada
Ratio Fosinopriltablet20 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-02-082008-08-01Canada
Riva-fosinopriltablet10 mgoralLaboratoire Riva Inc2005-06-292016-05-31Canada
Riva-fosinopriltablet20 mgoralLaboratoire Riva Inc2005-06-292016-05-31Canada
Teva-fosinopriltablet10 mgoralTeva Canada Limited2003-12-05Not applicableCanada
Teva-fosinopriltablet20 mgoralTeva Canada Limited2003-12-05Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fosinopriltablet20 mgoralApotex Inc2005-04-27Not applicableCanada
Apo-fosinopriltablet10 mgoralApotex Inc2005-04-27Not applicableCanada
Fosinopril Natablet10 mg/1oralApotex Corp.2005-05-18Not applicableUs
Fosinopril Natablet20 mg/1oralApotex Corp.2005-05-18Not applicableUs
Fosinopril Natablet40 mg/1oralApotex Corp.2005-05-18Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralCamber Pharmceuticals Inc.2007-09-17Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Fosinopril Sodiumtablet10 mg/1oralTeva Pharmaceuticals USA Inc2003-12-01Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralPhysicians Total Care, Inc.2004-11-18Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralAphena Pharma Solutions Tennessee, Inc.2004-04-23Not applicableUs
Fosinopril Sodiumtablet10 mg/1oralAurobindo Pharma Limited2011-03-30Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralUnit Dose Services2007-09-17Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralExelan Pharmaceuticals, Inc.2005-06-21Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralEon Labs, Inc.2004-04-23Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralCamber Pharmceuticals Inc.2007-09-17Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralSt Marys Medical Park Pharmacy2014-05-22Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralTeva Pharmaceuticals USA Inc2003-12-01Not applicableUs
Fosinopril Sodiumtablet10 mg/1oralGolden State Medical Supply2011-12-27Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralAphena Pharma Solutions Tennessee, Llc2005-06-21Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralAurobindo Pharma Limited2011-03-30Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralUnit Dose Services2007-09-17Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralEon Labs, Inc.2004-04-23Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralExelan Pharmaceuticals, Inc.2005-06-21Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-04-23Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralREMEDYREPACK INC.2016-01-04Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralGolden State Medical Supply2011-12-27Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralDispensing Solutions, Inc.2004-04-23Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralTeva Pharmaceuticals USA Inc2003-12-01Not applicableUs
Fosinopril Sodiumtablet20 mg/1oralPhysicians Total Care, Inc.2004-04-27Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralAurobindo Pharma Limited2011-03-30Not applicableUs
Fosinopril Sodiumtablet10 mg/1oralCamber Pharmceuticals Inc.2007-09-17Not applicableUs
Fosinopril Sodiumtablet10 mg/1oralbryant ranch prepack2007-09-17Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralAphena Pharma Solutions Tennessee, Llc2005-06-21Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralGolden State Medical Supply2011-12-27Not applicableUs
Fosinopril Sodiumtablet10 mg/1oralExelan Pharmaceuticals, Inc.2005-06-21Not applicableUs
Fosinopril Sodiumtablet10 mg/1oralEon Labs, Inc.2004-04-23Not applicableUs
Fosinopril Sodiumtablet10 mg/1oralPhysicians Total Care, Inc.2004-05-18Not applicableUs
Fosinopril Sodiumtablet40 mg/1oralAphena Pharma Solutions Tennessee, Inc.2004-04-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcecorSPA (Czech Republic)
MonoprilBristol-Myers Squibb
StarilBMS (United Kingdom)
Brand mixtures
NameLabellerIngredients
Fosinopril Sodium and HydrochlorothiazideEon Labs, Inc.
Salts
Name/CASStructureProperties
Fosinopril Sodium
88889-14-9
Thumb
  • InChI Key: TVTJZMHAIQQZTL-HREVRLCXSA-M
  • Monoisotopic Mass: 585.283133986
  • Average Mass: 585.6443
DBSALT000193
Categories
UNIIR43D2573WO
CAS number98048-97-6
WeightAverage: 563.6625
Monoisotopic: 563.301189343
Chemical FormulaC30H46NO7P
InChI KeyInChIKey=BIDNLKIUORFRQP-FKDWWROVSA-N
InChI
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
IUPAC Name
(2S,4S)-4-cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid
SMILES
CCC(=O)OC(OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[[email protected]]1C(O)=O)C1CCCCC1)C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids
Alternative Parents
Substituents
  • N-acyl-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Phosphinic acid ester
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organophosphorus compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
PharmacodynamicsFollowing oral administration, fosinopril is rapidly and completely hydrolyzed to its principle active metabolite, fosinoprilat. Hydrolysis is thought to occur in the gastrointestinal mucosa and liver. Fosinoprilat is a competitive inhibitor of ACE, a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of fosinoprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
Related Articles
AbsorptionAverage absolute absorption is 36%. The primary site of absorption is the proximal small intestine (duodenum/jejunum). Food slows the rate of absorption with no effect on the extent of absorption.
Volume of distributionNot Available
Protein bindingFosinoprilat is ≥95% protein bound
Metabolism

Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites.

SubstrateEnzymesProduct
Fosinopril
Not Available
FosinoprilatDetails
Route of eliminationAfter oral administration of radiolabeled fosinopril, approximately half of the absorbed dose is excreted in the urine and the remainder is excreted in the feces.
Half life12 hours
Clearance
  • 26 – 39 mL/min [healthy]
ToxicityHuman overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality. The most common adverse effects include dizzines, cough, fatigue, and headache.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fosinopril Action PathwayDrug actionSMP00149
Fosinopril Metabolism PathwayDrug metabolismSMP00594
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9532
Blood Brain Barrier-0.667
Caco-2 permeable-0.6561
P-glycoprotein substrateSubstrate0.6165
P-glycoprotein inhibitor IInhibitor0.7161
P-glycoprotein inhibitor IINon-inhibitor0.6774
Renal organic cation transporterNon-inhibitor0.812
CYP450 2C9 substrateNon-substrate0.7028
CYP450 2D6 substrateNon-substrate0.8128
CYP450 3A4 substrateSubstrate0.6729
CYP450 1A2 substrateNon-inhibitor0.8913
CYP450 2C9 inhibitorNon-inhibitor0.7438
CYP450 2D6 inhibitorNon-inhibitor0.9004
CYP450 2C19 inhibitorNon-inhibitor0.5725
CYP450 3A4 inhibitorNon-inhibitor0.7303
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6376
Ames testNon AMES toxic0.7141
CarcinogenicityNon-carcinogens0.8025
BiodegradationNot ready biodegradable0.8102
Rat acute toxicity2.8211 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9534
hERG inhibition (predictor II)Non-inhibitor0.5918
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc etobicoke site
  • Invagen pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Watson laboratories inc florida
  • Bristol myers squibb co pharmaceutical research institute
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral
Tabletoral10 mg
Tabletoral20 mg
Prices
Unit descriptionCostUnit
Monopril HCT 10-12.5 mg tablet1.71USD tablet
Monopril 10 mg tablet1.68USD tablet
Monopril 40 mg tablet1.67USD tablet
Monopril 20 mg tablet1.62USD tablet
Fosinopril Sodium-HCTZ 10-12.5 mg tablet1.61USD tablet
Fosinopril Sodium-HCTZ 20-12.5 mg tablet1.61USD tablet
Fosinopril sodium 20 mg tablet1.25USD tablet
Fosinopril sodium 40 mg tablet1.25USD tablet
Fosinopril sodium 10 mg tablet1.21USD tablet
Monopril 20 mg Tablet1.1USD tablet
Monopril 10 mg Tablet0.91USD tablet
Apo-Fosinopril 20 mg Tablet0.61USD tablet
Fosinopril 20 mg Tablet0.61USD tablet
Jamp-Fosinopril 20 mg Tablet0.61USD tablet
Mylan-Fosinopril 20 mg Tablet0.61USD tablet
Novo-Fosinopril 20 mg Tablet0.61USD tablet
Ran-Fosinopril 20 mg Tablet0.61USD tablet
Apo-Fosinopril 10 mg Tablet0.51USD tablet
Fosinopril 10 mg Tablet0.51USD tablet
Jamp-Fosinopril 10 mg Tablet0.51USD tablet
Mylan-Fosinopril 10 mg Tablet0.51USD tablet
Novo-Fosinopril 10 mg Tablet0.51USD tablet
Ran-Fosinopril 10 mg Tablet0.51USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5006344 No1993-01-102010-01-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point149-153 °CNot Available
water solubilityInsolubleNot Available
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00101 mg/mLALOGPS
logP4.71ALOGPS
logP5.49ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)3.87ChemAxon
pKa (Strongest Basic)-4.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.21 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity149.12 m3·mol-1ChemAxon
Polarizability61.17 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Sandra Gallego Pato, Antonio Palomo Coll, Francisco Palomo Nicolau, “Preparation of crystalline polymorphs of fosinopril sodium.” U.S. Patent US20050010054, issued January 13, 2005.

US20050010054
General References
  1. David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. [PubMed:11854791 ]
  2. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095 ]
External Links
ATC CodesC09AA09C09BA09
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelDownload (206 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Fosinopril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Fosinopril.
AcebutololFosinopril may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Acetazolamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Fosinopril.
AdapaleneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Adapalene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Fosinopril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Fosinopril.
AliskirenFosinopril may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Fosinopril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Fosinopril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Fosinopril.
AlprenololFosinopril may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideThe serum concentration of Fosinopril can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Fosinopril can be decreased when it is combined with Aluminum phosphate.
AmbrisentanFosinopril may increase the hypotensive activities of Ambrisentan.
AmifostineFosinopril may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Amiloride.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Fosinopril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Fosinopril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Fosinopril.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Fosinopril.
AmlodipineAmlodipine may increase the hypotensive activities of Fosinopril.
AmobarbitalAmobarbital may increase the hypotensive activities of Fosinopril.
Amyl NitriteThe risk or severity of adverse effects can be increased when Fosinopril is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Apraclonidine.
ApremilastThe risk or severity of adverse effects can be increased when Fosinopril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Fosinopril.
ArdeparinArdeparin may increase the hyperkalemic activities of Fosinopril.
AripiprazoleAripiprazole may increase the hypotensive activities of Fosinopril.
AtenololAtenolol may increase the hypotensive activities of Fosinopril.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Fosinopril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Fosinopril.
AzapropazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azapropazone.
AzathioprineFosinopril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Fosinopril.
BemiparinBemiparin may increase the hyperkalemic activities of Fosinopril.
BenazeprilFosinopril may increase the hypotensive activities of Benazepril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Fosinopril.
BenmoxinBenmoxin may increase the hypotensive activities of Fosinopril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Benoxaprofen.
BepridilFosinopril may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Fosinopril.
BethanidineBethanidine may increase the hypotensive activities of Fosinopril.
BimatoprostFosinopril may increase the hypotensive activities of Bimatoprost.
Bismuth SubcitrateThe serum concentration of Fosinopril can be decreased when it is combined with Bismuth Subcitrate.
BisoprololFosinopril may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Fosinopril can be decreased when it is combined with Boceprevir.
BosentanFosinopril may increase the hypotensive activities of Bosentan.
BretyliumFosinopril may increase the hypotensive activities of Bretylium.
BrimonidineFosinopril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Fosinopril.
BromfenacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Fosinopril.
BumetanideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bumetanide.
BupranololFosinopril may increase the hypotensive activities of Bupranolol.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Fosinopril.
Calcium carbonateThe serum concentration of Fosinopril can be decreased when it is combined with Calcium carbonate.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Fosinopril.
CanagliflozinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Canagliflozin.
CandesartanFosinopril may increase the hypotensive activities of Candesartan.
CandoxatrilFosinopril may increase the hypotensive activities of Candoxatril.
CaptoprilFosinopril may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Fosinopril can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Fosinopril.
CarprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Carprofen.
CarteololFosinopril may increase the hypotensive activities of Carteolol.
CarvedilolFosinopril may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Celecoxib.
CeliprololFosinopril may increase the hypotensive activities of Celiprolol.
CertoparinCertoparin may increase the hyperkalemic activities of Fosinopril.
ChloroquineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Chloroquine.
ChlorothiazideFosinopril may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Fosinopril.
CilazaprilFosinopril may increase the hypotensive activities of Cilazapril.
CiprofloxacinFosinopril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Fosinopril.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Fosinopril.
ClevidipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Fosinopril.
ClonidineFosinopril may increase the hypotensive activities of Clonidine.
ClonixinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clonixin.
CryptenamineFosinopril may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosinopril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Fosinopril.
CyclothiazideFosinopril may increase the hypotensive activities of Cyclothiazide.
D-LimoneneThe risk or severity of adverse effects can be increased when Fosinopril is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Fosinopril.
DapagliflozinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Fosinopril.
DebrisoquinFosinopril may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Fosinopril.
DeserpidineFosinopril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Fosinopril.
DexmedetomidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dexmedetomidine.
DiazoxideDiazoxide may increase the hypotensive activities of Fosinopril.
DiclofenacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenamide.
DiflunisalThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Fosinopril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fosinopril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Fosinopril.
DiltiazemDiltiazem may increase the hypotensive activities of Fosinopril.
DinutuximabThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dipyridamole.
DorzolamideFosinopril may increase the hypotensive activities of Dorzolamide.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fosinopril.
DoxazosinFosinopril may increase the hypotensive activities of Doxazosin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Fosinopril.
DrospirenoneFosinopril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Droxicam.
DuloxetineFosinopril may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Fosinopril.
EfonidipineFosinopril may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Empagliflozin.
EnalaprilFosinopril may increase the hypotensive activities of Enalapril.
EnalaprilatFosinopril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Fosinopril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Fosinopril.
EpirizoleThe risk or severity of adverse effects can be increased when Fosinopril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Fosinopril.
EplerenoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Eplerenone.
EpoprostenolFosinopril may increase the hypotensive activities of Epoprostenol.
EprosartanFosinopril may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosinopril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Fosinopril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Fosinopril.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Fosinopril.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Fosinopril.
Etacrynic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Fosinopril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril.
exisulindThe risk or severity of adverse effects can be increased when Fosinopril is combined with exisulind.
FelodipineFosinopril may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Fenbufen.
FenoldopamFosinopril may increase the hypotensive activities of Fenoldopam.
FenoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Flurbiprofen.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Fosinopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Fosinopril.
FurosemideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Furosemide.
GarlicThe serum concentration of Fosinopril can be decreased when it is combined with Garlic.
GuanabenzFosinopril may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Fosinopril.
GuanethidineFosinopril may increase the hypotensive activities of Guanethidine.
GuanfacineFosinopril may increase the hypotensive activities of Guanfacine.
HeparinHeparin may increase the hyperkalemic activities of Fosinopril.
HexamethoniumFosinopril may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Fosinopril.
HMPL-004The risk or severity of adverse effects can be increased when Fosinopril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Fosinopril.
HydralazineFosinopril may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideFosinopril may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideFosinopril may increase the hypotensive activities of Hydroflumethiazide.
IbuprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Fosinopril.
IcatibantThe risk or severity of adverse effects can be increased when Fosinopril is combined with Icatibant.
IloprostIloprost may increase the hypotensive activities of Fosinopril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Fosinopril.
IndapamideFosinopril may increase the hypotensive activities of Indapamide.
IndenololFosinopril may increase the hypotensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indoprofen.
IndoraminFosinopril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Fosinopril.
IproniazidIproniazid may increase the hypotensive activities of Fosinopril.
IrbesartanFosinopril may increase the hypotensive activities of Irbesartan.
IronThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Fosinopril.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Fosinopril.
KebuzoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ketorolac.
LabetalolFosinopril may increase the hypotensive activities of Labetalol.
LacidipineFosinopril may increase the hypotensive activities of Lacidipine.
Lanthanum carbonateThe serum concentration of Fosinopril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostFosinopril may increase the hypotensive activities of Latanoprost.
LeflunomideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Leflunomide.
LercanidipineFosinopril may increase the hypotensive activities of Lercanidipine.
LevobunololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Levobunolol.
LevodopaFosinopril may increase the orthostatic hypotensive activities of Levodopa.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Fosinopril.
LisinoprilFosinopril may increase the hypotensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Fosinopril.
LofexidineFosinopril may increase the hypotensive activities of Lofexidine.
LornoxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lornoxicam.
LosartanFosinopril may increase the hypotensive activities of Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Fosinopril.
LoxoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lumiracoxib.
MacitentanFosinopril may increase the hypotensive activities of Macitentan.
MagaldrateThe serum concentration of Fosinopril can be decreased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Magnesium salicylate.
Magnesium TrisilicateThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium Trisilicate.
ManidipineFosinopril may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mannitol.
MasoprocolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Fosinopril.
MecamylamineFosinopril may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Fosinopril.
MetamizoleThe risk or severity of adverse effects can be increased when Fosinopril is combined with Metamizole.
MethazolamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Fosinopril.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Fosinopril.
MethyclothiazideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Methyclothiazide.
MethyldopaFosinopril may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Fosinopril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Fosinopril.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Fosinopril.
MetipranololFosinopril may increase the hypotensive activities of Metipranolol.
MetolazoneFosinopril may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Fosinopril.
MibefradilFosinopril may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fosinopril.
MinaprineMinaprine may increase the hypotensive activities of Fosinopril.
MinoxidilMinoxidil may increase the hypotensive activities of Fosinopril.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Fosinopril.
MoclobemideMoclobemide may increase the hypotensive activities of Fosinopril.
MoexiprilFosinopril may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Fosinopril.
MoxonidineFosinopril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nabumetone.
NadololFosinopril may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Fosinopril.
NaftifineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Fosinopril is combined with NCX 4016.
NebivololFosinopril may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Fosinopril.
NepafenacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Fosinopril.
NicardipineFosinopril may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Fosinopril.
NifedipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Niflumic Acid.
NiguldipineFosinopril may increase the hypotensive activities of Niguldipine.
NilvadipineFosinopril may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Fosinopril.
NisoldipineNisoldipine may increase the hypotensive activities of Fosinopril.
NitrendipineFosinopril may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Fosinopril.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Fosinopril.
ObinutuzumabFosinopril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Fosinopril.
OlmesartanOlmesartan may increase the hypotensive activities of Fosinopril.
OlopatadineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Olsalazine.
OmapatrilatFosinopril may increase the hypotensive activities of Omapatrilat.
OrgoteinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Oxaprozin.
OxprenololFosinopril may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Oxyphenbutazone.
PapaverineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine.
ParecoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Parecoxib.
PargylineFosinopril may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Fosinopril.
PenbutololFosinopril may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Fosinopril.
PentoliniumFosinopril may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Fosinopril.
PerindoprilFosinopril may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Fosinopril.
PheniprazinePheniprazine may increase the hypotensive activities of Fosinopril.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Fosinopril.
PhenoxybenzamineFosinopril may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Fosinopril.
PhentolamineFosinopril may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Fosinopril.
PinacidilFosinopril may increase the hypotensive activities of Pinacidil.
PindololFosinopril may increase the hypotensive activities of Pindolol.
PiretanidePiretanide may increase the hypotensive activities of Fosinopril.
PirfenidoneThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Fosinopril.
PiroxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Fosinopril.
PolythiazideFosinopril may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Fosinopril.
PregabalinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Fosinopril.
PropacetamolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Propacetamol.
PropranololFosinopril may increase the hypotensive activities of Propranolol.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Fosinopril.
PTC299The risk or severity of adverse effects can be increased when Fosinopril is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine.
QuinaprilFosinopril may increase the hypotensive activities of Quinapril.
QuinethazoneQuinethazone may increase the hypotensive activities of Fosinopril.
QuinineQuinine may increase the hypotensive activities of Fosinopril.
RamiprilRamipril may increase the hypotensive activities of Fosinopril.
RasagilineRasagiline may increase the hypotensive activities of Fosinopril.
RemikirenRemikiren may increase the hypotensive activities of Fosinopril.
RescinnamineFosinopril may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Fosinopril.
ResveratrolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Fosinopril.
RiociguatFosinopril may increase the hypotensive activities of Riociguat.
RisperidoneFosinopril may increase the hypotensive activities of Risperidone.
RituximabFosinopril may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Rofecoxib.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Fosinopril.
SacubitrilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Fosinopril.
SalicylamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Fosinopril.
SalsalateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salsalate.
SaprisartanFosinopril may increase the hypotensive activities of Saprisartan.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Fosinopril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Fosinopril.
SecobarbitalSecobarbital may increase the hypotensive activities of Fosinopril.
SelegilineSelegiline may increase the hypotensive activities of Fosinopril.
SelexipagFosinopril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Fosinopril is combined with Seratrodast.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Fosinopril.
SildenafilSildenafil may increase the antihypertensive activities of Fosinopril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Fosinopril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Fosinopril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Fosinopril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Fosinopril.
SitaxentanFosinopril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sodium aurothiomalate.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril.
SpiraprilFosinopril may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Fosinopril.
SRT501The risk or severity of adverse effects can be increased when Fosinopril is combined with SRT501.
St. John's WortThe metabolism of Fosinopril can be increased when combined with St. John's Wort.
SulfasalazineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fosinopril.
TadalafilTadalafil may increase the antihypertensive activities of Fosinopril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fosinopril.
TelmisartanFosinopril may increase the hypotensive activities of Telmisartan.
TemocaprilFosinopril may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Fosinopril.
TenoxicamThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Terazosin.
TeriflunomideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Teriflunomide.
TerlipressinFosinopril may increase the hypotensive activities of Terlipressin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Fosinopril.
ThiamylalThiamylal may increase the hypotensive activities of Fosinopril.
ThiopentalThiopental may increase the hypotensive activities of Fosinopril.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Fosinopril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tiaprofenic acid.
TiboloneFosinopril may increase the hypotensive activities of Tibolone.
TicrynafenFosinopril may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Fosinopril.
TinzaparinTinzaparin may increase the hyperkalemic activities of Fosinopril.
TipranavirThe serum concentration of Fosinopril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Fosinopril.
TizanidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tizanidine.
TolazolineFosinopril may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Fosinopril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Fosinopril.
TorasemideTorasemide may increase the hypotensive activities of Fosinopril.
TrandolaprilFosinopril may increase the hypotensive activities of Trandolapril.
TranilastThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fosinopril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Fosinopril.
TravoprostTravoprost may increase the hypotensive activities of Fosinopril.
TreprostinilTreprostinil may increase the hypotensive activities of Fosinopril.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Fosinopril.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Fosinopril.
TrichlormethiazideFosinopril may increase the hypotensive activities of Trichlormethiazide.
TrimazosinFosinopril may increase the hypotensive activities of Trimazosin.
TrimethaphanFosinopril may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Fosinopril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Fosinopril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Fosinopril.
UnoprostoneFosinopril may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Fosinopril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Fosinopril.
VardenafilVardenafil may increase the antihypertensive activities of Fosinopril.
VerapamilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Verapamil.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Fosinopril.
XylometazolineFosinopril may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Fosinopril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Fosinopril.
ZileutonThe risk or severity of adverse effects can be increased when Fosinopril is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Fosinopril is combined with Zomepirac.
Food Interactions
  • Do not take calcium, aluminum, magnesium or iron supplements, or antacids within 2 hours of taking this medication.
  • Fosinopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Herbs that may attenuate the antihypertensive effect of fosinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of fosinopril.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Ondetti MA: Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation. 1988 Jun;77(6 Pt 2):I74-8. [PubMed:2836111 ]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
  4. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23